Fall Clinical Dermatology

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses how dermatologists and clinicians can work towards increasing diversity and inclusion in treating patients with skin of color with plaque psoriasis.

Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University's Feinberg School of Medicine, discussed type 2 inflammation in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

Patients with diverse skin types can experience diagnostic delays, access to care issues, and quality-of-life burdens that a navigator program may be able to help alleviate.

With the recent development of various new treatments, April Armstrong, MD, MPH, discusses the new standards she and other dermatologists hope to set for treating patients with atopic dermatitis (AD).

Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.

The results from this 5-year, open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, lists barriers to care for dermatology patients.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, describes different methods dermatologists can use to treat atopic dermatitis (AD).

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses unique challenges dermatologists face when treating patients with skin of color, who may present differently from White patients.

April Armstrong, MD, MPH, of University of California, Los Angeles, discussed how recent biologics advancements improved moderate-to-severe atopic dermatitis (AD) treatment.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, provides on overview of the treatment landscape in patients with skin of color with plaque psoriasis.

April Armstrong, MD, MPH, of University of California, Los Angeles, gave an overview of her Fall Clinical Dermatology session on treating atopic dermatitis (AD) in patients with diverse skin tones and weighed in on how to address related treatment barriers.

April Armstrong, MD, MPH, of University of California, Los Angeles, explained that the main health care gap within the atopic dermatitis (AD) realm is that many clinicians are not comfortable prescribing systemic medications.

Recognizing that skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa present differently in skin of color can prevent delays in diagnosis and treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.

There are many drugs that have been around for years and others with strong data awaiting FDA approval that are beneficial in treating conditions like atopic dermatitis and alopecia areata, said James Q. Del Rosso, DO.

Posters presented at Fall Clinical Dermatology 2023 found that dupilumab had effective and safe results when received in a 5-year period for atopic dermatitis.

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis.

Patients with alopecia areata found effective treatment with baricitinib, which had long-term efficacy and positive results.

A panel hosted at Fall Clinical Dermatology 2023 highlighted how dermatologists can help to address acne and psoriasis in their patients.

Atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) can present differently in diverse patients, potentially leading to delayed diagnosis and therefore delayed treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.

Both adolescents and adults saw improvements with the use of ruxolitinib or povorcitinib to treat their nonsegmental vitiligo.

The FDA approval of topical ruxolitinib 1.5% cream changed the game for vitiligo treatment in both adult and pediatric patients, said Raj Chovatiya, MD, PhD, assistant professor of dermatology at Northwestern University's Feinberg School of Medicine.

A panel held at Fall Clinical Dermatology 2023 emphasized the role of Janus kinase (JAK) inhibitors in several skin conditions and highlighted new therapies in the space.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, addresses how dermatologists need to focus on patient needs when determining the best use of new biologics in moderate to severe atopic dermatitis.

Janus kinase (JAK) inhibitors are not only efficacious in terms of skin disease improvement, but also in terms of itch management, explained Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology.

The landscape for biologics to treat patients with psoriasis looks excellent, said April Armstrong, MD, MPH, professor and chief of dermatology at UCLA.

The 2023 Fall Clinical Dermatology conference will take place in Las Vegas and be livestreamed from October 19 to 22; topics of interest to be covered include atopic dermatitis (AD), Janus kinase (JAK) inhibitors, and psoriasis.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, gives a preview of his session on mild to moderate atopic dermatitis (AD) in skin of color.